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Background: Low bone mineral density is common in adults with cystic fibrosis. Children with good lung function compared to controls matched
for body size have normal bone mineralisation. There are few data in large unselected populations of children.
Methods: All children between five and 16 years were invited to take part. Disease severity was assessed. Bone mineral measurements using a
GE-Lunar Prodigy densitometer were expressed as age and gender matched Z-scores. Bone mineral apparent density for L2–L4 was estimated
and data from UK Caucasian children used to create age and gender specific reference ranges for predicted values. Z-scores were calculated.
Total body analysis utilised the Molgaard method. Blood was sampled for measurement of 25-hydroxyvitamin D, and parathyroid hormone
levels.
Results: 107 children entered the study. 18 and 10 children had low areal and apparent bone mineral density respectively. Short, narrow
bones were common. Fifteen children reported 22 fractures, 20 with associated trauma. The best predictors of bone status were ZBMI and
percent predicted FEV1.
Conclusions: Bone mineral density corrected for body size was normal in over 90% of children. These results are similar to previously
reported results in small studies of children with well preserved respiratory function.
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doi:10.1016/j.jcf.2008.04.004Low bone mineral density (BMD) in patients with cystic
fibrosis (CF) probably results from multiple aetiologies [1–13].
A high prevalence of osteoporosis and osteopenia has been
documented in adults with CF [14] but the impact of some of the
above factors e.g. disease severity [15], BMI and nutritional
deficiencies [16], and age at onset of puberty [17], may be
reduced in today's children with CF because of improved anti-
infective, anti-inflammatory and nutritional therapies [18–20].
Bone mineral density (BMD) is measured by dual energy X-
ray absorptiometry (DXA) scans. The DXA scan provides an
areal measurement and may therefore underestimate BMD in
children with short, narrow bones [21,22], complicating the
interpretation of results in some patients with CF. When control
groups have been matched for body size as well as age and
gender, to allow for this potential underestimation, children with
CF have shown smaller but normally mineralised bones [23,24].d by Elsevier B.V. All rights reserved.
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and were restricted to children with well preserved lung
function. Other studies have combined data from children and
adults and/or adolescents [2,4,25]. We know of only two other
studies reporting data from large unselected paediatric popula-
tions [26,27]. The aim of our exploratory cross-sectional study
was to measure BMD in a large unselected group of children
and adolescents with CF attending a paediatric centre and to
assess the association of BMD status with parameters which
may affect bone.
1. Patients and methods
All patients aged between 5 to16 years attending the Leeds
Regional Paediatric CF Clinic were invited to take part in this
cross sectional study. Parents who did not wish their children to
participate were not asked to state a reason. Using self assessed
Tanner [28] staging patients were sub-divided by gender into
prepubertal (Tanner stage 1), early pubertal (Tanner stages 2
and 3) and late pubertal (Tanner stages 4 and 5) groups. Age and
gender matched Z-scores for height (ZHt), weight (ZWt) and
BMI (ZBMI) were derived from the 1990 British reference
standards [29].
Age at diagnosis of CF and fracture history, including age and
site of fracture, were recorded. The effect of CF genotype was
analysed using one-way ANOVA and three mutation classifica-
tions; homozygous for ΔF508, heterozygous for ΔF508, and
other.
Overall disease severity was evaluated by the Shwachman–
Kulcycki (SK) clinical score [30]. Severity of lung disease
was assessed by the Northern chest radiography score (CXR
Northern) [31], the number of intravenous (IV) antibiotic courses
received during the previous year, and measurements of
respiratory function expressed as percent predicted (Polgar) [32]
using standard spirometry (Vitalograph Compact 11): forced vital
capacity {FVC}, forced expiratory volume in 1 s {FEV1} and the
average forced expiratory flow rate over the middle 50% of the
FVC {FEF25–75% .}. The clinical severity of CF airway disease as
an expression of FEV1 values was defined as mild (70 to 90%),
moderate (40 to 69%) or severe (b40%).
Inhaled corticosteroid use was categorized as a mean daily
dose of none, up to 800 μg, and N800 μg. Oral corticoste-
roid courses were categorized as none, short term (b1 week),
or continuous (≥ two months treatment) over the previous
12 months.
Dual energy X-ray absorptiometry (DXA) measurements
were made at the lumbar spine and total body using a GE-Lunar
Prodigy densitometer, (software version 5.0). The study utilized
the Thin and Standard scan modes with mode selection based
on the subject's height and weight. Measured in-vivo BMD
precision (%CV) for the two modes were Thin: 1.9, 0.8 and
Standard: 0.6, 0.85 for lumbar spine and total body respectively
[33].
Bone mineral density (BMD) was measured at the lumbar
spine region L2–L4 (aSBMD) and expressed as age and gender
matched Z-scores (ZaSBMD) derived from the manufacturers
UK reference ranges for Caucasian children. Since DXA is anareal density measurement, to reduce the effect of body size,
bone mineral apparent density (BMAD) for the lumbar spine
region L2–L4 (SBMAD) was estimated using the method
of Kroger [34]. This method models the spine region as a
cylindrical volume derived from the projected area. Data from a
local database of 901(489F) Caucasian children were used to
create age and gender specific reference ranges for predicted
SBMAD values (SBMADp) [35].
Values for ZSBMAD were calculated from: (SBMAD−
SBMADp) /SD(SBMADp).
Total body BMD (TBBMD), total body bone mineral content
(TBBMC) and total body bone area (TBArea) measurements
were made. Age and gender matched Z-scores for ZTBBMD
were derived from the manufacturer's UK reference ranges for
Caucasian children. To reduce the effect of body size on total
body bone analysis the method of Molgaard [36] was used. This
method assesses bone mineralisation in children with a three
step analysis of growth and bone parameters; a) height for age
(to allow for short bones), b) total body bone area for height (to
allow for narrow bones), c) total body bone mineral content for
total body bone area (to allow for light bones). Predicted values
for total body bone mineral content (TBBMCp) and total body
bone area (TBAreap) were calculated from the local reference
ranges for Caucasian children. ZTBBMC (to identify light bones)
and ZTBArea (to identify narrow bones) were derived from the
equation:
(Measured−predicted) /SD(predicted) and used with ZHt
(to allow for short bones) in the analysis.
In this study bone size corrected values of ZSBMD,
ZTBArea and ZTBBMC were selected as the best parameters
to represent the bone status of the study group.
Fasting blood was sampled for measurement of 25-hydroxy-
vitamin D (25-OHD), and parathyroid hormone (PTH), normal
reference range 10–35 ng/l. A 25-OHD level ≥30 ng/ml was
defined as normal. Levels 10–29 ng/ml and b10 ng/ml were
defined as vitamin D insufficiency and vitamin D deficiency
respectively.
Statistical tests were carried out using SPSS v11.5 (LEAD
Technologies Inc, USA) or Microsoft EXCEL 2000 with
Analyse It v1.73 (Analyse It Software Ltd, UK). The Shapiro–
Wilk non-parametric statistical test was used to determine
whether the data were normally distributed. Non-parametric
statistics and Spearman correlation coefficients were used to
study the relationship between bone parameters and Vitamin D
and SK score. Pearson correlation coefficients were used to
determine relationships between disease severity and body size
parameters with bone parameters. A multivariate stepwise
model was used to assess the association between independent
variables sex, age, pubertal status, ZHt, ZWt, ZBMI, IV, CXR,
SKscore, fracture and Vitamin D status with size corrected bone
parameters to select the combination of variables that were
predictive of the bone parameter. Inclusion was set at the 5%
significance level.
Analysis of Variance (ANOVA) was used to compare bone
parameters by CF genotype. Comparison of Z-score results with
zero reference values were performed with single sample tests.
Values in the text are reported as mean±standard deviation (sd)
Table 1
CF children physical characteristics, lung function and biochemical values
Females Males
Pubertal stage Pre Early Late Pre Early Late
(n) (20) (19) (10) (29) (12) (17)
Age (yr) 8.2(2.1) 12.6(2.2) 15.3(1.0) 8.2(1.5) 12.5(1.3) 14.7(1.7)
Age(yr) at diagnosis 1.50 (0.1 to 3.0) 1.5 (0.02 to 2.2) 0.12 (0 to 13.0) 0.2 (0.1 to 0.6) 0.7 (0.1 to 3.0) 0.2 (0.1 to 0.5)
Ht (cm) 127.4(14.7) 149.7(8.6) 156.9(5.2) 126.8(9.5) 143.6(5.7) 162.8(9.8)
Z-Ht −0.2(1.0) −0.3(1.2) −0.7(1.0)* −0.35(0.7)* −1.1(0.8)*** −0.3(0.9)
Wt (kg) 22.7 (20 to 28.7) 38.8(6.7) 50.1(7.7) 25.6(4.8) 34.2(5.6) 48.3(11.3)
Z-Wt −0.5(0.9)* −0.8(1.4)* −0.6(1.1) −0.5* (−0.8 to −0.3) −1.2(1.1)** −0.7(1.3)
BMI(kg/m2) 15.5(1.8) 17.7(2.6) 20.3(2.7) 15.8(1.5) 16.5(1.7) 17.9(2.5)
Z-BMI −0.2 (−0.9 to 0.2) −0.7(1.2)* −0.1(1.1) −0.2(0.9) −0.8(1.1)* −0.8(1.4)
Lung Function
SKscore 93 (85 to 97) 88.5 (75 to 95) 87.2(9.6) 95 (90 to 95) 79.2(14.6) 90 (85 to 95)
FEV1 70.1(16.1) 71 (40 to 82) 68.7(17.1) 85.7(14.5) 62.1(17.4) 73.6(14.8)
FVC 86.0(15.8) 76.0(19.3) 91.6(11.2) 101 (94 to 111) 76.6(14.4) 91.6(17.6)
FEF25–75% 49.8(21.6) 55(20 to 81) 36.5 (20 to 108) 61.9(21) 34.2(17.4) 53.6(19.1)
CXR Northern 5.1(2.5) 8.3(4.5) 6.1(3.1) 4.7(2.5) 9.3(3.2) 8.2(3.7)
Biochemical
Vit D (ng/ml) 17.6(7.9) 16(6.6) 16.3(14.6) 19 (14 to 21.3) 20.7(7.1) 17.3(8.2)
PTH (ng/l) 58 (33 to 69) 49.5 (35 to 73) 36 (28 to 78) 40(21.3) 34(12.8) 40(17.9)
Mean (SD), Median (95%CI), Significantly different from 0 (*pb0.05, **pb0.01, ***pb0.0005).
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significant.
The study was approved by the Leeds East Ethics Com-
mittee. Written informed consent was obtained from the parent.
2. Results
One hundred and seven, (49F), of 138 children in the defined
age group were enrolled in the study. Mean age was 11.1 years
(range 5.1 to 16.6). No child showed pubertal delay according to
self-assessed Tanner staging [28]. Forced vital capacity, FEV1,
and FEF25–75% measurements were performed in 101 of the 107
children and expressed as percentage predicted normal for gender
and height. Seven patients (7%, 5F) had severe, 36 (36%, 18F)Table 2
CF children bone parameters
Female
Pubertal stage Pre Early Late
aSBMD 0.680(0.128) 0.854(0.121) 1.049(0.183)
SBMAD 0.287(0.036) 0.321(0.035) 0.374(0.059)
SBMADp 0.302 (0.296 to 0.317) 0.356(0.023) 0.384(0.011)
ZaSBMD −0.5(0.9)* −1.1(1.7)** −0.9(2.0)
ZSBMAD −0.7(1.0)** −1.0(1.1)*** −0.3(1.6)
TBBMD 0.841(0.073) 0.956(0.065) 1.055(0.096)
TBBMC 906(325) 1435(240) 1922(370)
TBBMCp 825 (636 to 1011) 1411(215) 1934(316)
TBArea 1056(284) 1494(179) 1811(226)
TBAreap 1127(300) 1595(198) 1860(154)
ZTBBMD −0.1(0.55) −0.4(1.1) −0.4(1.2)
ZTBBMC 0.2(0.7) 0.4(1.0) −0.2(1.5)
ZTBArea −1.0(0.9)*** −1.0(1.0)*** −0.4(1.5)
Mean(sd) Median(95%CI) Significantly different from zero *pb0.05, **pb0.01, **moderate, and 58 (57%, 23F) mild lung disease according to %
predicted FEV1 values. Patients showed mild growth impairment
and reduced bodyweight with the greatest deficits observed in the
male early pubertal groups (Table 1). The children (n=31; 17
female) who did not enter the study were non-significantly
younger, (mean age 9.2 years, p=0.07), with similar FEV1%
measurements, (mean 77.3% v. 78.4%). Eighteen (58%) of these
children had mild, and 13 (42%) moderate, lung disease as
defined by % predicted FEV1 values. There were no significant
differences between participants and non-participants for weight,
height, or BMI standard deviation scores.
The numbers of children with CF-associated low BMD
(Z-scores≤−2.0) [37] were: ZaSBMD, 18 (10F, 17%);
ZSBMAD, 10(7F, 9%); ZTBBMD, four (2F, 4%); ZTBArea, 19Male
Pre Early Late
0.705(0.078) 0.704(0.078) 0.933 (0.88 to 1.006)
0.293(0.082) 0.277(0.031) 0.318(0.045)
0.287 (0.286 to 0.289) 0.305(0.008) 0.328(0.018)
0.0(0.75) −1.5(1.1)*** −0.8(1.9)
0.2(1.0) −0.8(1.0)** −0.3(1.3)
0.890(0.057) 0.904(0.057) 1.049 (1.023 to 1.077)
984(224) 1230(174) 1926 (1688 to 2211)
935(213) 1230(170) 1927 (1747 to 2232)
1098(191) 1357(142) 1918(350)
1121(180) 1505(129) 2115(279)
0.6(0.6) −0.6(0.8) 0.1(1.6)
1.0(0.9)*** 0(1.0) −0.2 (−0.32 to 0.21)
−0.3(0.9)* −1.5(0.8)*** −1.5(1.1)***
*pb0.0005.
Fig. 3. Z-scores: total body bone area for height (narrow bones).
Fig. 4. TBBMC for total body bone area (light bones).
Fig. 1. ZSBMAD for pubertal stages.
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significantly reduced in pre-pubertal girls and in early
pubertal boys and girls (Fig. 1), indicating that bone mineral
deficits are not due to bone size and the 9% with low BMD
require longitudinal monitoring.
Height for age Z-scores showed significant decreases
(short bones) in the female late pubertal group and the pre
and early pubertal male groups (Fig. 2). ZTBArea showed
significant decreases (narrow bones) in all children except
girls in the late pubertal group. The most significant de-
creases were in the early and late pubertal boys (Fig. 3).
ZTBBMC for bone area, low values indicating light bones,
were normal except in pre pubertal boys who showed a highly
significant increase (Fig. 4).
The number of intravenous antibiotic courses during the
previous year was documented for 98 children. Fifty-three
children had not received intravenous antibiotic treatment.
Fifteen children had received one course; 11 had received two
courses; nine had received three courses; six had received four
courses; and four children had received five to eight courses.
Children who had received any intravenous antibiotic treatment
in the previous 12 months had significantly lower bone para-
meter Z scores for ZSBMAD, −0.7(1.1) v −0.2(1.1), p=0.04;
ZTBArea, −1.2(1.2) v −0.6(1.0), p=0.002.Fig. 2. Z-scores: height for age (short bones).Age at diagnosis in 101 children was sub-divided into
b1 year (n=67) and N1year (n=34). No significant differences
were observed between the two groups for bone parameter Z-
scores. Sixty-six (62%) of the children were DF508 homo-
zygous, 31 (29%) heterozygous, and 10 (9%) “other”. The only
significant association of the ΔF508 mutation with bone and
body size Z-scores was a decrease in ZHt in the ΔF508/other
group, p=0.02.
Fifteen (16%) of the children reported 22 fractures. A history
of associated trauma was obtained from all but two children.
No rib fractures and only one lumbar vertebral fracture wereTable 3
Correlation of bone Z-scores with disease severity indices and body size
parameters
ZSBMAD ZTBArea ZTBBMC
SKScore 0.31** 0.46*** 0.17
FEV1 0.48*** 0.48*** 0.30**
CXR −0.29** −0.34** −0.12
ZHt 0.14 0.19 −0.2
ZWt 0.35*** 0.62*** 0.22*
ZBMI 0.35*** 0.71*** 0.34**
*pb0.05 **pb0.005 ***pb0.0001.
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observed for children with a history of fracture: ZTBBMC, −0.4
(1.0) v 0.5(1.1), p=0.005. Differences in ZSBMAD and
ZTBArea did not reach significance.
Vitamin D levels were obtained in 95 (44F) children. Vita-
min D deficiency (b10 ng/ml) was present in 14 (15%) children,
4 (3F) children in the prepubertal group, 4 (4F) in the early
pubertal group and 6 (3F) in the late pubertal group. Vitamin D
insufficiency (10–29 ng/ml) occurred in 74 (78%) children and
only 7 (7%) children had normal Vitamin D levels (≥30 ng/ml).
No correlations were observed between bone parameter Z-
scores and Vitamin D levels.
Significantly lower bone parameter Z-scores were observed
for the Vitamin D deficiency group compared to the Vitamin D
insufficiency group, ZSBMAD;−1.0(1.3) v −0.4(1.1), ZTBArea;
−1.5(1.4) v −0.9(1.0), ZTBBMC; −0.2(1.2) v 0.4(1.1), (pb0.03
to 0.002). No significant differences were observed for ZHt. PTH
results in 85 patients were sub-divided into two groups, normal
(n=36) and elevated (n=49). No significant differences were
observed for bonemineral status. There was a negative correlation
between vitamin D levels and PTH, r=−0.36, pb0.001.
Inhaled corticosteroid (ICS) use was recorded for 94 child-
ren. Those receiving ICS in a daily dose N800 µg (27, 29%) had
significantly lower Z-scores for ZWt (pb0.001) and ZBMI
(pb0.05) than children receiving no ICS (38, 40%) or up to
800 µg daily (29, 31%). No significant differences were ob-
served with bone size corrected Z-scores. Oral corticosteroid
administration (none 81; short term 7; continuous 13) showed
no significant effect on the above Z-scores.
The correlation coefficients between disease severity indices
and body size Z-scores with bone parameter Z-scores are shown
in Table 3. Pubertal status was not included in this analysis as
we were only concerned with disease severity and body size.
FEV1, ZWt and ZBMI had significant positive relationships
with all three bone parameter Z-scores. The results of the
multivariate stepwise regression model using all parameters
with significant correlations with the three bone parameter Z-
scores are given in Table 4. FEV1 was the only significantly
predictive parameter associated with ZSBMAD (pb0.0001).
FEV1 (p=0.01) and ZBMI (pb0.0001) were the only signi-
ficant predictive parameters associated with ZTBArea. ZBMITable 4
Multivariate stepwise regression with bone size corrected Z-scores as the
dependant variable: disease severity and body size parameters as the
independent retained variables
ZBMI FEV1 Fx Vit D
status
Intecept
(SE)
Coeff
(SE)
Coeff
(SE)
Coeff
(SE)
Coeff
(SE)
R2
ZSBMAD −2.50
(0.42)
0.03
(0.006)****
0.23
ZTBArea −1.41
(0.36)
0.63
(0.08)****
0.012
((0.005)**
0.54
ZTBBMC 0.01
(0.31)
0.30
(0.10)***
−0.69
(0.31)*
0.64
(0.32)*
0.20
*pb0.05 ** p=0.01 ***pb0.005 ****pb0.0001.(pb0.005) was also the most significant predictive parameter
for ZTBBMC. Fracture and Vitamin D status (both pb0.05)
were only slightly predictive. Sex, age, pubertal status, ZWt,
ZHt, SK score, CXR and IV were not significant independent
predictors in the multiple linear regression analysis.
3. Discussion
The major deficit in BMD in an unselected population of
children with CF was found at the L2 to L4 level in the lumbar
spine. Seventeen per cent showed low bone mineral density.
However, height for age, and total body bone area for height
Z scores showed significant decreases indicating a high
prevalence of short, narrow bones [38]. When the DXA mea-
sured BMD value was corrected for body size, ZSBMAD
showed 9% of children with low BMD. As bone mass depends
on both the size and density of the bone a difference in bone
mass may reflect a difference in the bone size or in the density of
the bone. A low BMDmeasurement in a small for chronological
age child may only be due to a small body size. Caution should
be used when correcting for body size using height and weight
as normal healthy children will tend to be younger than
chronically ill children when matching for height and weight.
This is especially true for children with CF who may have
slower growth rates than normal children.
Recent studies have reported normal overall bone mineral
status in well nourished children with mild disease when
controls were matched for body size as well as age and gender
[23,24,39,40]. These studies were limited, however, by small
numbers and exclusion of children with long term corticosteroid
use. The children in our study mostly had mild to moderate
disease with significantly low ZBMI scores found only in the
early pubertal groups, and only seven percent with FEV1
values b40% predicted normal. Nonetheless, our results in a
large unselected cross-section of children, including those
prescribed corticosteroid therapy, are importantly broadly con-
sistent with those smaller and more selective studies. Buntain
et al [26] found normal bone mineral parameters in children
b10 years of age but contrary to our results, significantly
lower values for TBBMD in adolescents. This may reflect the
higher upper age of 20 years compared to 16.6 years in the
present study.
The 17% prevalence of low spine BMD differs markedly
from the 33% to 35% rate reported in 113 patients between three
and 18 years in the Milan paediatric CF centre [27]. Correction
for body size by calculation of BMAD resulted in a fall in
prevalence to nine percent in our study but had no effect on the
Milan figures. This disparity may reflect the different propor-
tions of severe and mildly affected patients in Leeds and Milan,
(7% v. 12%, and 57% v. 47% respectively), and the greater use
of inhaled and oral corticosteroids in Milan (90% v. 60%, and
32% v. 20% respectively). Intravenous corticosteroids were
administered to an unspecified number of children in Milan, but
to none in Leeds. There was no significant difference in the
nutritional status of the two populations as determined by
weight or height standard deviation scores, (−0.45 and −0.6,
and −0.49 and −0.42 respectively).
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secretion, and inhibit intestinal calcium absorption. This study
showed a steroid effect on total body and areal BMD Z scores
only for inhalation treatment at a dose N800 µg a day and no
differences when results were corrected for body size. The
lack of any association between oral corticosteroid use and
BMD values might reflect the small number of patients
prescribed this medication (short term {7}, continuous {13}).
Despite the lack of conclusive evidence, these results suggest
that corticosteroid treatment, at high dose or long term, should
be prescribed with caution and the need for the prescription
regularly reviewed.
The main role of vitamin D in childhood and adolescence is
to maximise BMD by regulating small intestinal calcium
absorption and renal tubular calcium losses. Serum concentra-
tions of 25-OHD should be at least 30 ng/ml with optimal levels
between 36–40 ng/ml [41]. In vitamin D insufficiency intestinal
calcium absorption is inefficient, ionised calcium levels fall, and
PTH levels rise. To preserve homeostasis more calcium is
mobilised from bone. Most children in this study had 25-OHD
deficiency or insufficiency despite routine daily supplementa-
tion with 800-1600IU (20–40 mcg) vitamin D in the form of
ergocalciferol. At the time of the study all vitamin D prepara-
tions were combined with vitamin A supplements. Although
plasma vitamin D levels were measured annually, high co-
existing vitamin A concentrations may have prevented an
increase in vitamin D supplementation [42]. It is our present
practice to use separate vitamin D supplements. The optimal 25-
OHD concentration is that which maximally suppresses PTH
[42]. Forty-nine of 85 patients had raised PTH levels and a
significant negative correlation was observed between PTH and
vitamin D levels. This study highlights the need to monitor 25-
OHD levels and to increase supplementation until satisfactory
values are obtained.
There is a negative correlation between peak bone mineral
accrual and peak height velocity with age at menarche [43].
Maximal accrual velocities occur across puberty, [26,44,45]
with most adult bone mass achieved by the end of ado-
lescence [44,46]. Significantly decreased Z-scores for both
areal and apparent spinal BMD were found in pre- and early
pubertal girls and early pubertal boys in this study with
improved values in both late pubertal groups, suggesting the
possibility of a delayed growth/puberty effect with some
catch-up in later childhood. Although some centres now
report no delay in onset of puberty [17], this is not universal
[2,7,8], and those showing no delay may have reduced sex
hormone levels compared to age-matched controls when
values are adjusted for Tanner stage [17]. Although ZaSBMD
and ZSBMAD values in late pubertal groups were not
significantly different from zero in this study, the data raise
concerns. It is imperative that people with CF have their bone
status monitored into late adolescence/ adulthood to ascertain
when they reach peak bone mass. This will require reference
ranges from 16–20 years.
In keeping with other studies [2–4,47] we have shown a
significant association between disease severity and re-
duced BMD. Pre-pubertal boys showed a significant increasein ZTBBMC and the highest Z-scores for aSBMD, SBMAD,
and TBBMD. This group also had the best lung function and
chest X-ray scores. ZBMI and FEV1% predicted were most
strongly associated with bone status. As children with poor
FEV1 are likely to be less active than their healthier peers it
is possible some of the deficit in bone mineral could be
attributed to low levels of exercise. A reduction in BMI could
result from either a reduction in lean tissue mass (LTM) or fat
mass. Both of these factors have been associated with a
reduction in BMD [27]. In addition LTM, as a measure of
muscle mass, is an independent predictor of bone mass in
healthy subjects [48].
Children requiring at least one course of intravenous anti-
biotic treatment had significantly lower BMD scores. These
findings may be linked by the catabolic state and high level of
circulating pro-inflammatory cytokines associated with acute
respiratory exacerbations and chronic severe infection. Cyto-
kines stimulate osteoclast induced bone resorption and decrease
bone formation [6,49]. As reported by Bianchi et al [27] no
association was found between bone health parameters and the
ΔF508 CFTR gene mutation.
Twenty-two fractures were reported by 15 children (14%).
Only two fractures were atraumatic and there were no dif-
ferences in ZSBMAD between the children with and without
a fracture history. Increased bone fragility and atraumatic
fractures have been reported in adults with CF [41] espe-
cially in those with severe disease [10] but not in children
[26,50]. The reported fracture rate in this study is probably
no greater than in the non-CF population [50]. It should be
noted that although DXA measurements predict fracture
risk in non-CF adults with a doubling of risk for each SD
below the mean, no fracture threshold has been identified for
children [21], although the incidence of forearm fracture in
healthy children has been associated with a low bone density
values [51].
In view of the relatively low power of this study it may now
be appropriate to perform a larger multi-centre study to confirm
these results.
4. Conclusion
In conclusion, low bone mineral density was uncommon in
an unselected group of children and adolescents with CF and in
almost half of these the low BMD value reflected short, narrow
bones rather than true bone mineral deficiency. Even with
inclusion of children prescribed corticosteroids these results are
similar to previously reported results in small studies of children
with well preserved respiratory function who showed normal
mineralisation of smaller than normal bones. Decreased pre-and
early pubertal BMD Z scores suggested a possible delayed
pubertal effect on bone mineralisation. There was a significant
association between BMD and disease severity, with ZBMI and
FEV1 the best predictors. Lower bone parameter Z scores were
seen in the vitamin D deficiency group and therefore vitamin D
levels should be optimised by regular assessment and appro-
priate dietary supplements. Corticosteroids should be prescribed
with caution.
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